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Abstract 
The cardiac phosphoprotein phospholemman (PLM) regulates the cardiac sodium pump, 
activating the pump when phosphorylated, and inhibiting it when palmitoylated. Protein 
palmitoylation, the reversible attachment of a 16 carbon fatty acid to a cysteine thiol, is catalyzed 
by DHHC-containing palmitoyl acyltransferases. The cell surface palmitoyl acyltransferase 
DHHC5 regulates a growing number of cellular processes, but relatively few DHHC5 substrates 
have been identified to date. We examined the expression of DHHC isoforms in ventricular 
muscle and report that DHHC5 is among the most abundantly expressed DHHCs in the heart, 
and localizes to caveolin-enriched cell surface microdomains. DHHC5 co-immunoprecipitates 
with PLM in ventricular myocytes and transiently transfected cells. Overexpression and silencing 
experiments indicate that DHHC5 palmitoylates PLM at two juxtamembrane cysteines, C40 and 
C42, although C40 is the principal palmitoylation site. PLM interaction with and palmitoylation 
by DHHC5 is independent of the DHHC5 PDZ binding motif, but requires a ~120 amino acid 
region of the DHHC5 intracellular C-tail immediately after the fourth transmembrane domain. 
PLM-C42A but not PLM-C40A inhibits the Na pump, indicating PLM palmitoylation at C40 but 
not C42 is required for PLM-mediated inhibition of pump activity. In conclusion, we 
demonstrate an enzyme-substrate relationship for DHHC5 and PLM, and describe a means of 
substrate recruitment not hitherto described for this acyltransferase. We propose that PLM 
palmitoylation by DHHC5 promotes phospholipid interactions that inhibit the Na pump. 
 
 
 
Significance Statement 
Dynamic palmitoylation at the cell surface by the acyl transferase DHHC5 regulates a plethora of 
physiological processes, from endocytosis to synaptic plasticity. Here we report that DHHC5 is 
abundantly expressed in cell surface caveolar microdomains in cardiac muscle, and that the Na 
pump regulator phospholemman is a substrate for DHHC5. Palmitoylation of phospholemman 
C40 by DHHC5 reduces Na pump activity. DHHC5 interacts with phospholemman independent 
of its PDZ binding motif, via a region of its intracellular carboxyl tail that has not hitherto been 
implicated in substrate recognition. This suggests that it may be possible to selectively 
manipulate DHHC5 activity by blocking the recruitment of specific substrates to the active site 
by the carboxyl tail. 
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Introduction 
Protein palmitoylation, the reversible attachment of a 16 carbon fatty acid to a cysteine thiol 
via a thioester bond, is catalyzed by palmitoyl acyltransferases (DHHC-PATs); there are 23 
human isoforms (1). These zinc-finger-containing enzymes typically have 4 transmembrane 
(TM) domains, with a conserved ~50 amino acid cysteine-rich cytosolic core located between 
TM2 and 3 which contains a conserved Asp-His-His-Cys (DHHC) motif, the active site. In 
contrast, the intracellular amino and carboxyl termini are poorly conserved, and likely contribute 
to DHHC isoform substrate selectivity (1). DHHC-PATs are expressed throughout the secretory 
pathway, but DHHC5 is widely recognized as one of very few cell-surface localized PATs (2, 3). 
The final 4 amino acids of DHHC5 form a canonical class II PDZ binding motif, which interacts 
with post-synaptic density protein-95 (PSD-95 (2)), although PSD-95 is not itself a DHHC5 
substrate. 
An appreciation is now growing that protein palmitoylation turns over rapidly (minutes) for 
certain proteins (4-8). For example, dynamic surface membrane protein palmitoylation by 
DHHC5 underlies a novel form of endocytosis, massive endocytosis (MEND), in which up to 
70% of the cell surface membrane is internalized (7, 8). Calcium overload leading to 
mitochondrial stress causes transient openings of the mitochondrial permeability transition pore 
(MPTP) and release of coenzyme A into the cytoplasm, where it is acylated to form a substrate 
for DHHC5 to palmitoylate surface membrane proteins (7). The clustering of acylated proteins in 
lipid ordered domains leads to MEND by as-yet unidentified mechanisms in multiple cells types. 
Importantly, MEND occurs during reperfusion of anoxic cardiac muscle, and is inhibited by 
interventions classically reported to reduce MPTP opening and protect against reperfusion injury, 
such as adenosine and cyclosporin A (8). DHHC5 knockout hearts in which MEND is essentially 
absent show significantly enhanced functional recovery following anoxia-reperfusion (8), 
strongly implicating DHHC5 and the MEND pathway in reperfusion injury. 
Interestingly, MEND is accelerated in the presence of the Na pump regulatory subunit 
phospholemman (PLM) (7), which inhibits the Na pump when palmitoylated (9, 10), activates 
the pump when phosphorylated (11, 12) and relieves the pump from oxidative inhibition by 
becoming glutathionylated (13). The biochemical interplay of multiple post-translational 
modifications on this small protein is complex. Palmitoylation occurs at both cytosolic cysteines 
(C) 40 and 42 (9), but glutathionylation only at C42 (13), where it presumably competes with 
palmitoylation. Phosphorylation of PLM by PKA promotes its palmitoylation (9). A number of 
alternative cellular functions have been proposed for PLM – including regulation of the cardiac 
Na/Ca exchanger (NCX1 (14)), voltage gated Ca channels (15), and cell volume through 
formation of a homo-oligomeric ion channel (16). While palmitoylated PLM oligomers 
undoubtedly exist in cardiac muscle (17), their cellular function remains unclear.  
In this study we defined the molecular control of PLM palmitoylation, and investigated the 
functional roles of the two PLM palmitoylation sites in the regulation of the Na pump. We report 
that PLM is a substrate for DHHC5, which is abundantly expressed in caveolar microdomains in 
cardiac muscle. Truncation analysis indicates interaction of PLM with and palmitoylation of 
PLM by DHHC5 requires a region of the DHHC5 carboxyl terminus close to the transmembrane 
domain, but is independent of the DHHC5 PDZ binding motif. 
 
Results 
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DHHC association with PLM- We hypothesized that palmitoylation of PLM may involve the 
formation of a stable complex with the palmitoylating DHHC enzyme(s). We therefore 
investigated the association of PLM and DHHC isoforms in co-immunoprecipitation experiments 
from FT-293 cells constitutively and stably expressing human PLM that were transfected with 
HA-tagged murine DHHCs (Fig 1). DHHCs 4, 5, 6 and 7 consistently co-purify PLM to a much 
greater extent than any other DHHC isoforms. DHHCs 3, 15, 16, 22 and 23 also consistently co-
immunoprecipitate with PLM, but always to a lesser extent. Expression and solubilization of 
DHHC isoforms showed significant inter-isoform variability, and we were consistently unable to 
solubilize DHHC 8 (Fig 1), so were unable to determine its ability to associate with PLM. 
Normalizing the quantity of purified PLM to the amount of each DHHC isoform 
immunoprecipitated identifies DHHC5 as a quantitatively significant binding partner of PLM. 
 
DHHC expression profile in cardiac muscle- To identify those DHHC isoforms which are 
expressed in rat cardiac myocytes we employed a quantitative PCR approach similar to one that 
successfully determined the expression profile of DHHC isoforms in HEK cells (18). mRNA was 
prepared from 4 independent rat hearts. The expression profile of DHHCs in cardiac muscle is 
expressed as the geometric mean relative to β-actin and GAPDH (each heart was assessed in 
duplicate) in Fig. 2A. DHHCs 2, 4 and 5 are the most abundantly expressed in the heart at the 
level of mRNA, with DHHCs 19 and 22 below the level of detection for this assay. 
 
DHHC5 localization in cardiac muscle- Since DHHC5 is one of very few cell-surface 
localized PATs (2, 3), is abundantly expressed in cardiac muscle, and associates with PLM, we 
focused on the relationship between PLM and DHHC5. Like PLM and the Na pump, we found 
that DHHC5 was predominantly localized to buoyant caveolin-enriched microdomains in rat 
ventricular myocytes (Fig. 2B). We therefore investigated the association of PLM and DHHC5 
by co-immunoprecipitation from rat ventricular myocyte lysates (Fig. 2C). PLM phosphorylated 
at S63 or S68 both co-immunoprecipitate with DHHC5. We were unable to assess co-
purification of DHHC5 with unphosphorylated PLM as our antibody specific for 
unphosphorylated PLM is raised in rabbit and showed significant interference when blotting for 
DHHC5. Since the pool of PLM phosphorylated at S63 is not associated with the Na pump in 
cardiac muscle (17), our data suggest a direct interaction between DHHC5 and PLM, rather than 
one dependent upon another pump subunit. 
 
Effect of DHHC5 overexpression and silencing on PLM palmitoylation- Given the physical 
interaction between PLM and DHHC5, we investigated whether PLM is a DHHC5 substrate by 
overexpressing DHHC5 in FT-293 cells constitutively and stably expressing PLM. 
Overexpression of HA-tagged DHHC5 increased palmitoylation of PLM in these cells, as well as 
increasing the palmitoylation of the established DHHC5 substrate flotillin 2 (Fig 2D). When we 
overexpressed DHHC5 in cells expressing PLM-YFP C40A or PLM-YFP C42A, both variants 
showed increased palmitoylation, suggesting that both sites are DHHC5 substrates. 
Overexpression of DHHC isoforms may result in non-specific substrate palmitoylation, so we 
also silenced DHHC5 and measured the impact on PLM palmitoylation (Fig 2E). Palmitoylation 
of both PLM and flotillin 2 were significantly reduced when DHHC5 was silenced. In both over-
expression and silencing experiments we observed no change in palmitoylation of H-ras, which 
is palmitoylated by DHHC9 in the Golgi apparatus (19). 
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DHHC5 truncations- We investigated the region(s) of DHHC5 that interact with PLM, and 
the functional importance of interaction(s) for PLM palmitoylation by making truncations based 
on a DHHC5 disorder prediction (Fig S1, the sites of truncation are marked in the disorder 
prediction). DHHC5 was truncated in its disordered intracellular carboxyl terminus (C-tail) by 
introducing stop codons to produce mutants N218X, T334X, and R526X. Wild type and 
truncated DHHC5 were transiently expressed with constitutively expressed PLM in FT-293 cells, 
and their association assessed by immunoprecipitating the HA-tagged DHHC5. Fig 3A indicates 
that while wild type, R526X and T334X DHHC5 co-purify with PLM to the same extent, 
association of N218X DHHC5 with PLM is essentially abolished. Interestingly, we were unable 
to detect the association of the DHHC5 substrate flotillin 2 with wild type or truncated DHHC5 
in the same experiment, suggesting that DHHC5 can palmitoylate certain substrates without 
forming stable complexes (Fig 3A). 
We next investigated whether palmitoylation of PLM by DHHC5 was influenced by DHHC5 
truncations. DHHC catalytic activity relies on auto-palmitoylation within the DHHC motif, 
followed by transfer of the palmitoyl group to the substrate (20), which is unlikely to be 
influenced by mutations outside the DHHC-containing cysteine rich domain. Fig 3B indicates 
that while all DHHC5 truncation mutants are palmitoylated, and therefore likely retain catalytic 
activity, mutant N218X is no longer able to palmitoylate PLM. Hence the interaction with and 
palmitoylation of this DHHC5 substrate requires a region of DHHC5 between N218 and T334. 
Interestingly, despite its failure to associate with any DHHC5 constructs expressed, 
palmitoylation of flotillin 2 was also reduced in cells expressing N218X DHHC5 compared to 
cells expressing WT DHHC5, suggesting that the C-tail may also play a role in enabling flotillin 
2 palmitoylation. 
 
Quantitative analysis of PLM palmitoylation sites-. We used resin-assisted capture of acylated 
proteins (Acyl-RAC) to assess the palmitoylation of wild type, C40A and C42A PLM-YFP in 
stably transfected cell lines, which are characterized in Fig S2. Fig. 4A indicates that although 
both PLM cysteines are clearly palmitoylated (since both mutants were purified by acyl-RAC), 
C40 is the principal palmitoylation site in FT-293 cells (because PLM-YFP C42A is 
substantially enriched by the acyl-RAC procedure), with only a modest amount of palmitoylation 
at position C42. 
Acyl-RAC is incapable of distinguishing singly from multiply palmitoylated proteins, so in 
order to determine whether PLM is singly or doubly palmitoylated in cardiac myocytes we 
developed a PEG switch assay to measure palmitoylation. Free cysteines in lysates from rat 
ventricular myocytes were blocked with maleimide in the presence of SDS, and after removal of 
the alkylating agent, lysates were treated with either 5kDa or 10kDa PEG-maleimide in the 
presence or absence of neutral hydroxylamine (ha). Cleavage of the thioester bond by ha allows 
cysteine PEGylation, which is visualized as an increase in molecular mass using SDS PAGE. We 
validated this technique using the constitutively palmitoylated protein caveolin 3 (Fig. 4B). 
Caveolins are palmitoylated at three cysteine residues (21), and three PEGylated forms of 
caveolin 3 were clearly visible when using 5kDa PEG maleimide. We only detected a single 
PEGylated form of PLM in the same samples (Fig. 4B), suggesting that the majority of PLM in 
cardiac myocytes is singly palmitoylated. 
 
PLM palmitoylation at C40 inhibits the Na pump- Molecular models of the PLM / Na pump 
complex (Figs 4C, 4D) indicate that the side chain of PLM C42 is orientated towards the pump α 
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subunit, and C40 is orientated away. Palmitoylation of C42 (with incorporation of the palmitate 
into the lipid bilayer) may reorientate PLM helix 3 (H3) towards the α subunit in order to inhibit 
the pump, possibly through an effect on the recently-described Na entry pathway (22), or an 
influence on the transition between E1 and E2 states (23). Conversely, palmitoylation of C40 on 
the opposite side of H3 would oppose such a movement by re-orientating H3 in the opposite 
direction. This raises the possibility that while the overall effect of PLM palmitoylation on the 
pump is inhibitory, the individual palmitoylation sites may have opposing effects on pump 
activity through their reorientating effects on PLM H3. Palmitoylation-induced rearrangements 
of PLM H3 may also influence the interaction of other cytosolic elements of PLM with the pump 
α subunit. 
We measured Na pump activity as the ouabain-sensitive uptake of 86Rb by cells expressing 
inducible wild type, C40A and C42A PLM-YFP. For simplicity, pump activity following 
induction of PLM is expressed as a percentage of the activity in the absence of PLM in each 
experiment. As we have reported previously (9), induction of wild type PLM-YFP inhibits the 
Na pump (Fig. 4E). In contrast, PLM-YFP C40A is without effect on pump activity, while PLM-
YFP C42A inhibits the pump (Fig. 4E). Under these conditions neither PLM itself (9) nor the 
palmitoylation status of PLM (Fig S2) influence cell surface expression of the pump α subunit. 
Thus functional effects on the pump are the consequence of an influence of PLM palmitoylation 
on pump activity (rather than cell surface expression). Hence the inhibitory effect of PLM 
palmitoylation on the pump is via palmitoylation of PLM C40, which is consistent with our 
finding that this is the principal palmitoylation site. 
 
Discussion 
Here we establish an enzyme-substrate relationship between DHHC5 and PLM, the mechanism 
by which DHHC5 targets PLM, and the palmitoylation site in PLM that regulates the Na pump. 
 
Substrate recruitment by DHHC5- The importance of DHHC5 in a variety of biological 
processes, from MEND to synaptic plasticity (24), is currently emerging. This investigation 
highlights one means by which DHHC5 substrates are recruited to the enzyme active site – via 
its extended disordered C-tail. DHHC5 palmitoylation of PLM is supported by and requires 
direct interaction of DHHC5 with PLM, while it does not require PDZ protein interaction. 
DHHC5 binding partners identified to date (GRIP1 and PSD-95) bind DHHC5 through its PDZ 
binding motif, not the disordered C-tail (2, 25). PLM is the first DHHC5 substrate found to 
physically associate with a different region of DHHC5. We propose the region between N218 
and T334 of DHHC5 interacts with the carboxyl terminus of PLM (from S37 to R72), since both 
are located cytoplasmically. Notably, palmitoylation of flotillin 2, which does not physically 
associate with DHHC5, requires the same region of DHHC5 as PLM. The failure of flotillin 2 to 
co-immunoprecipitate with DHHC5 may reflect a lower affinity interaction than PLM, or a 
different means of recruiting this particular substrate – possibly indirectly via an adaptor protein, 
much as is the case for protein kinases. Macromolecular complex assembly as a means of 
lending specificity to post-translational modifications is well-characterized in the biology of 
protein kinases (with A-kinase anchoring proteins perhaps the best example in the heart (26)), 
but remains uninvestigated for DHHCs. 
Understanding the mechanisms by which DHHCs recruit substrates is clearly key to 
understanding the spatial and temporal control of protein palmitoylation. Disorder predictions for 
all human DHHCs (Fig S3) indicate that the majority of family members consist of a core 
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ordered cytosolic cysteine rich domain with relatively disordered intracellular N and C termini. 
DHHCs 2 and 3 possess notably little disorder, which may account for their tractability in cell-
free systems (20). In some isoforms the region of C-tail disorder is relatively large (for example 
DHHCs 1, 5, 8, 14). Our experimental data together with these disorder predictions are 
consistent with previous reports that regions outside the cysteine-rich domain are responsible for 
substrate recruitment to DHHCs (27-29). We suggest that disordered domain interactions 
underlie substrate recognition by (and hence substrate specificity of) some DHHCs. It is notable 
that DHHC2, the only isoform other than DHHC5 at the cell surface, does not co-
immunoprecipitate with PLM and is predicted to be highly ordered. DHHC2, like DHHC5, is 
abundantly expressed in cardiac muscle, and reported to functionally couple to the Na pump in 
the heart (8), but our data suggest this is achieved by a mechanism either independent of PLM, or 
without the formation of a stable complex. 
 
PLM palmitoylation sites- We have previously speculated that given the orientation of PLM C42 
towards the pump α subunit, palmitoylation at this site rather than PLM C40 mediates pump 
inhibition by palmitoylated PLM (10). That this is unequivocally not the case is one conclusion 
of the present investigation: PLM-mediated inhibition of the Na pump absolutely requires its 
palmitoylation at C40. PLM is principally palmitoylated at C40 in HEK cells, whereas we 
estimate less than 10% of PLM C42 is palmitoylated. Our PEGylation assay confirms that PLM 
is predominantly singly palmitoylated in myocytes. Since we find both PLM C40 and C42 are 
palmitoylated by DHHC5, it is reasonable to infer that DHHC5 exhibits the same preference for 
PLM C40 in cardiac myocytes as it does in HEK cells. Site-specific reagents to determine 
palmitoylation site occupancy in cardiac tissue have resisted development in our hands, and we 
acknowledge the limitation of extrapolating the DHHC5 preference for C40 in HEK cells to 
myocytes. The molecular basis for this preference remains undetermined, but may reflect the 
relative inaccessibility of PLM C42 to DHHC5 when complexed with the Na pump (Fig 4D). 
 
Functional implications of DHHC5-mediated pump regulation- DHHC5 regulates Na pump 
density at the cell surface via MEND (8). Consistent with our previous investigation (9) we 
found no influence of PLM or its palmitoylation status on cell surface expression of the pump α 
subunit (Fig S2). Hence we propose that palmitoylation of PLM C40 by DHHC5 has a direct 
inhibitory effect on pump enzymatic activity at the cell surface, and therefore regulates cardiac 
contractility through the functional coupling of the Na pump and NCX (12). DHHC5 therefore 
inhibits the pump through both palmitoylation of PLM and the MEND pathway. The 
convergence of multiple signaling pathways on PLM highlights the key role of this regulatory 
protein in control of intracellular Na in cardiac myocytes (30). Intracellular Na influences a vast 
array of cellular processes in the heart (12), including contractility via NCX, and mitochondrial 
energetics (31). The steep reliance of NCX activity on the transmembrane Na gradient means 
that even small changes in intracellular Na have a substantial influence on systolic Ca. 
Remarkably, intracellular Na exerts a greater influence on peak systolic Ca than the activity of 
any of the cardiac Ca transporters (32), so the change in Na pump activity caused by 
palmitoylation of PLM C40 by DHHC5 is likely to be functionally significant in the heart. 
It is widely reported that PLM reduces the pump’s Na affinity in both intact cells (12), and 
following reconstitution in proteoliposomes (33). Molecular dynamics simulations suggest an 
interaction between the PLM carboxyl terminus (R65, R66, R70) and the pump N domain may 
be responsible for at least part of this functional inhibition (33). The structural imposition of a 
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membrane-anchoring fatty acid on PLM C40 may influence the interaction between elements of 
the PLM carboxyl terminus and the pump intracellular domains, but it is more probable that 
PLM palmitoylation influences the pump within the membrane bilayer itself, which is also a site 
of physical contact between these proteins (34, 35). Palmitoylation is well-established as 
regulating protein partitioning to membrane microdomains (36). Phospholipid interactions with 
the pump α subunit can directly regulate the pump (37), and reconstitution experiments suggest 
that the phospholipid composition of a particular membrane bilayer modifies the regulatory 
influence of PLM (33, 38). Therefore we suggest that palmitoylation of PLM C40 modifies 
regulatory phospholipid interactions in order to inhibit the pump. 
 
Conclusions- By combining truncation analysis with co-immunoprecipitation and acyl-RAC, we 
demonstrate recruitment and palmitoylation of the DHHC5 substrate PLM requires a region of 
the DHHC5 intracellular C-tail. 
 
Methods 
Materials & Antibodies- Unless indicated otherwise, all reagents were obtained from Sigma 
Chemical Company (Poole, UK) and were of the highest grade available. Antibodies were as 
previously described (9). Anti-PLM and anti-HADHA were from Abcam, anti-DHHC5 was from 
Sigma, anti-clathrin heavy chain was from BD Biosciences, anti-ras was from Millipore, and 
anti-hemagglutinin A (HA) was from Roche.  
 
Plasmids, cell lines, transfection and silencing- Plasmids encoding HA-tagged murine DHHC 
isoforms were generously provided by Professor Masaki Fukata, Division of Membrane 
Physiology, National Institute for Physiological Sciences, Japan. 
HEK-derived FT-293 cells expressing canine PLM-YFP under the control of a tetracycline 
sensitive promoter are described elsewhere (9). FT-293 cells expressing tet-inducible PLM-YFP 
C40A and PLM-YFP C42A were generated in an identical manner using the Invitrogen Flip-In 
T-REx system. An additional FT-293 line constitutively expressing un-tagged human PLM was 
also generated using the Invitrogen Flip-In system. 
All transfections of plasmid DNA used Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions. 
siRNA targeted to human DHHC5 was predesigned and supplied by Qiagen. Knockdown 
used two siRNAs (20nM each), which were delivered using Trans-IT X2 (Cambridge 
Bioscience), according to the manufacturer’s instructions. Cells were harvested 72 hours after 
transfection. 
 
Co-immunoprecipitation- Proteins were solubilized in 2mg/ml C12E10 in PBS supplemented 
with protease inhibitors, and targets captured overnight at 4˚C using antibodies pre-immobilized 
on protein G Sepharose beads (GE Life Sciences) or anti-HA beads (Roche) as appropriate, as 
described previously (17). 
 
Purification of palmitoylated proteins- Acylated proteins were captured on pre-equilibrated 
thiopropyl Sepharose (GE Life Sciences) in the presence of 200mM hydroxylamine following 
blockade of free thiols with methyl methanethiosulfonate, as described in detail elsewhere (17). 
We routinely assess palmitoylation stoichiometry by comparing target protein abundance in the 
starting (unfractionated) cell lysate to that captured during the acyl-RAC procedure. The resin-
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captured fraction is reduced in volume 5-fold compared to the unfractionated cell lysate, so 
stoichiometrically palmitoylated proteins are 5-fold enriched, and enrichment less than 5-fold 
indicates sub-stoichiometric palmitoylation (17). 
 
Adult rat ventricular myocytes- Calcium-tolerant adult rat ventricular myocytes (ARVM) 
were isolated by retrograde perfusion of collagenase in the Langendorff mode.  
 
PEG switch- Cells were lysed in 2.5% SDS, 100mM HEPES, 1mM EDTA pH 7.4 and free 
cysteines alkylated by addition of 100mM maleimide and incubation at 40˚C for 4h. Excess 
unreacted maleimide was removed by acetone precipitation, and protein pellets extensively 
washed with 70% acetone, dried, then resolubilised in 1% SDS, 100mM HEPES, 1mM EDTA 
pH 7.4. Acylated proteins were PEGylated using 2mM 5kDa or 10kDa PEG-maleimide (Sigma) 
in the presence of 200mM hydroxylamine (ha, pH 7.4) for 2 h at room temperature. An identical 
reaction in which ha was replaced with 200mM NaCl served as a negative control. 
 
Molecular models of Na pump / PLM complex- We used our existing model of PLM and the 
Na pump, based on the structure of the pig enzyme in the E2 state (12). 
 
86Rb uptake measurements- Na pump activity was measured as ouabain-sensitive 86Rb uptake 
by cells cultured on poly-L-lysine coated 12-well multiwell dishes. All 86Rb uptake 
measurements were made in the presence of the Na ionophore monensin (Sigma) to ensure 
consistent intracellular Na between groups, and the Na/K/2Cl cotransporter inhibitor bumetanide 
(Sigma) to reduce background uptake of 86Rb. Cells were equilibrated in 20mM NaCl, 120mM 
NMDG.Cl, 1mM MgCl2, 1mM CaCl2, 5mM KCl, 10mM HEPES, 10mM glucose, 10µg/ml 
monensin, 100µM bumetanide pH 7.4 for 20-30 min at 37˚C, then preincubated ± ouabain 
(100µM) at 37˚C for 5 min before initiating 86Rb uptake by the addition of 1µCi/ml 86Rb per 
well. Cells were then incubated for 15min at 37˚C before 86Rb uptake was stopped by rapidly 
washing multiwell dishes by successive immersion in three baths of ice cold PBS. Cells were 
lysed in 1% Triton X-100 in PBS, the 86Rb content of lysates measured in a liquid scintillation 
counter, and the protein content of lysates measured using a Bradford assay with bovine serum 
albumin as standard. 
Preliminary experiments showed linear ouabain sensitive and insensitive 86Rb uptake between 
5 and 20 min under these conditions. In experiments in which NMDG.Cl was replaced with 
NaCl in the extracellular buffer (i.e. extracellular NaCl 140mM), ouabain-sensitive 86Rb uptake 
rate approximately doubled, confirming that the presence of 10µg/ml monensin in this buffer 
was sufficient to match intracellular Na to extracellular Na, and also indicating that in the 
presence of 20mM extracellular NaCl, Na pump activity was being measured close to the Km for 
Na. Ouabain-sensitive 86Rb uptake was typically >90% of total 86Rb uptake. 
 
mRNA preparation & quantitative PCR- mRNA was isolated from rat hearts that were briefly 
perfused in the Langendorff mode to remove contaminating blood, then snap frozen in liquid 
nitrogen. mRNA was prepared using the SV Total RNA Isolation System (Promega) according 
to the manufacturer’s instructions. Briefly, hearts were powdered by grinding in liquid nitrogen, 
and RNA prepared from 60mg of pulverized tissue. cDNA was prepared from 200ng RNA using 
the GoScript Reverse Transcription System (Promega) according to the manufacturer’s 
instructions. 
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The mRNA expression of each DHHC was quantified relative to the geometric mean of β-
actin and GAPDH using Fast Start Universal SYBR Green Mastermix (Roche) in a 25µl reaction 
using an ABIPrism 7000 real-time PCR machine. Reactions were performed in 25µl volumes 
with 0.2µM primers. cDNA from four independent heart samples (55–115ng of cDNA) was used 
per reaction. Cycling conditions were 50 °C for 2 min, 95 °C for 10 min, followed by 40 cycles 
of 95 °C for 15 s, and 60 °C for 1 min. All of the primers were previously validated with 
efficiencies calculated to be within 0.1 of the control using the equation e = 10(-1/slope) − 1. The 
internal reference controls were endogenous β-actin and GAPDH detected using Qiagen primer 
sets Rn_Actb_1_SG QT00193473 and Rn_Gapd_1_SG QT00199633. DHHC primers were 
designed and validated in house except for DHHCs 6 (Rn_Zdhhc6_1_SG QT02382807), 19 
(Rn_Zdhhc19_1_SG QT01575462) and 25 (RnZdhhc25_1_SG QT00436163), which were 
purchased from Qiagen.  
 
Sucrose gradient fractionation- Caveolin-enriched buoyant membranes were prepared from 
freshly isolated rat ventricular myocytes using a discontinuous sucrose gradient as described 
previously (17). 
 
Site directed mutagenesis- All mutations were introduced using the QuikChange site directed 
mutagenesis kit (Agilent), and confirmed by sequencing. The codon encoding N218 of murine 
DHHC5 was mutated to a stop codon using the oligonucleotide primers 
GGCTAGGGGACGCACAACCTGAACAGGTTACAGG and 
CCTGTAACCTGTTCAGGTTGTGCGTCCCCTAGCC. The codon encoding T334 of murine 
DHHC5 was mutated to a stop codon using the oligonucleotide primers 
CGAACACACCTCAGCCTGGCTTAATGAGGATAGCAG and 
CTGCTATCCTCATTAAGCCAGGCTGAGGTGTGTTCG. The codon encoding R526 of 
murine DHHC5 was mutated to a stop codon using the oligonucleotide primers 
CTGGCCCACCACACTGAGAACCCTCACC and 
GGTGAGGGTTCTCAGTGTGGTGGGCCAG. 
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Figure legends 
 
Figure 1 
DHHC isoform association with PLM. PLM principally co-immunoprecipitates with DHHCs 4, 
5, 6 and 7. Transiently expressed HA tagged DHHC isoforms were immunoprecipitated from 
FT-293 cells stably expressing PLM. EV: empty-vector transfected cells. Blots are representative 
of 3 independent experiments. Light chain of the immunoprecipitating antibody is labeled in HA 
blots.  
 
Figure 2 
DHHC expression profile and palmitoylation of PLM. A: The expression profile of DHHCs in 
cardiac muscle is expressed as the geometric mean relative to β-actin and GAPDH (n=4). An 
essentially identical expression profile was obtained normalizing to β-actin only or GAPDH only. 
B: DHHC5 localizes to buoyant caveolin-enriched microdomains with PLM and the Na pump α 
subunit in ventricular myocytes. Sonicated ventricular homogenates were separated using a 
standard discontinuous sucrose gradient. Fractions were collected from the top of the gradient. 
Caveolin-enriched membranes are found in fractions 4 and 5, while bulk sarcolemmal (marker 
protein, clathrin heavy chain) and mitochondrial membranes (maker protein, HADHA 
(Hydroxyacyl Coenzyme A dehydrogenase)) are exclusively found in dense membranes. C: 
PLM and DHHC5 are physically associated in ventricular muscle. PLM phosphorylation states 
(S63, S68) were immunoprecipitated from ventricular lysates and immunoblotted as shown. +: 
unfractionated ventricular lysate. D: DHHC5 overexpression increases PLM palmitoylation in 
FT-293 cell stably expressing wild type PLM, C40A PLM-YFP and C42A PLM-YFP. Flotillin 2 
palmitoylation is also elevated in the same cells (palm: palmitoylated proteins purified by acyl-
RAC, *: p<0.05). E: DHHC5 was silenced in FT-293 cells. Palmitoylation of both PLM and 
Flotillin 2 was significantly reduced in the absence of DHHC5. Inhibiting palmitoylation of PLM 
increases its degradation rate (9), so the steady state expression of PLM was reduced when 
DHHC5 was silenced. UF: unfractionated cell lysate. 
 
Figure 3 
The DHHC5 C-tail is required for palmitoylation of PLM. A: Effect of DHHC5 truncations on 
its association with PLM and flotillin 2. Note the sensitivity to proteolysis characteristic of 
disordered proteins. PLM associates with DHHC5 until a region between N218 and T334 is 
removed. Flotillin 2 is not found associated with DHHC5 in these experiments. (UF: 
unfractionated cell lysate.) B: Influence of DHHC5 truncations on substrate palmitoylation. 
Palmitoylation of PLM is significantly reduced when the region of DHHC5 that interacts with 
PLM is removed. Flotillin 2 palmitoylation is also reduced in the presence of the N218X 
truncation compared to wild type DHHC5. (palm: palmitoylated proteins, *: p<0.05).  
 
Figure 4 
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Analysis of PLM palmitoylation sites. A: Palmitoylated proteins (palm) were purified by acyl-
RAC from FT-293 cells expressing wild type, C40A and C42A PLM. The relative enrichment 
compared to unfractionated cell lysates (UF) indicates PLM C40 is the principal palmitoylation 
site. B: PEG switch assay from ventricular myocytes. Free cysteines were alkylated and lysates 
incubated in the presence of 5kDa or 10kDa PEG maleimide ± hydroxylamine (ha) to hydrolyze 
thioester bonds. PEGylation of previously palmitoylated cysteines retards mobility on SDS 
PAGE. Caveolin 3 is triply palmitoylated and PLM singly palmitoylated in ventricular myocytes 
(arrowheads). C: Position of PLM palmitoylation sites relative to the pump α subunit. View 
approximately perpendicular to the membrane from the cytoplasm. PLM is red, α subunit 
transmembrane region is blue and β subunit is wheat. Helices H2, H3 and H4 of PLM are labeled. 
D: C42 of PLM is orientated towards the α subunit, and C40 away. The α subunit P domain is 
yellow. E: Na pump activity was measured as ouabain-sensitive 86Rb uptake by cells following 
induction of wild type (WT), C40A or C42A PLM-YFP. For simplicity, pump activity is 
expressed as a percentage of the activity in the same cells in which PLM expression was not 
induced. Wild type and C42A PLM inhibit the Na pump, but C40A PLM does not (n=7; **: 
p<0.01). 
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Supplementary Methods 
Characterization of PLM-YFP expressing cell lines- PLM-YFP was immunoprecipitated with 
the monoclonal antibody DSHB-GFP-4C9, which was obtained from the Developmental Studies 
Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, 
Department of Biology, Iowa City, IA 52242. 
Representative fractions of cell surface proteins were prepared by briefly treating cells were 
with sulfo-NHS-SS-biotin for 10min at 37˚C to biotinylate integral surface membrane proteins 
with extracellular primary amines, which were purified using streptavidin Sepharose (GE 
Healthcare) as described previously (1). 
 
Supplementary Results 
DHHC disorder prediction- Many proteins contain local regions that fail to form well-defined 
three dimensional structures. These disordered regions can adopt multiple structures and are 
often involved in protein-protein interactions and molecular recognition, with an accompanying 
disorder to order transition (3). Aromatic amino acids, cysteine and histidine are usually under-
represented in disordered regions, whereas polar amino acids such as glutamate, aspartate, lysine 
and serine are more abundant (4, 5). We used a pattern recognition algorithm, regional order 
neural network (RONN, (6)) to detect disordered regions in human DHHC5. Fig S1 indicates 
that while the transmembrane domains and DHHC-containing cysteine-rich domain (between 
TMs 2 and 3) are relatively ordered (values < 0.5), the intracellular C-terminus (commencing at 
R213) is largely disordered (values > 0.5), which may imply a role in molecular recognition of 
DHHC5 substrates and / or binding partners. Other disorder predictors (PONDR-FIT (7), 
DISOPRED (8)) also suggest a disordered C-terminus for DHHC5. 
We used PONDR-FIT to produce disorder predictions for all human DHHC isoforms (Fig S3). 
The intracellular cysteine rich domain including the DHHC motif is predicted to be highly 
ordered in all isoforms except DHHC12. DHHC23 is notable for having a disordered region 
immediately prior to the cysteine rich domain. With the exception of DHHC4, all DHHC 
isoforms possess a disordered intracellular N-terminus before the first transmembrane domain, 
although in the case of DHHCs 13 and 17 (which contain ankyrin repeats in the N-terminus) this 
disordered region is small. Apart from DHHC24 (which has an extracellular C-terminus), all 
isoforms also contain some disorder in the intracellular C-terminus after the final transmembrane 
domain. In some isoforms this region of C-terminal disorder is relatively large (for example 
DHHCs 1, 5, 8, 14), while in others only a small region is apparent (for example DHHCs 3, 4, 6, 
7, 12, 13, 16, 17, 18, 21, 23). 
 
Characterization of tet-inducible cell lines expressing PLM-YFP C40A and PLM-YFP C42A- 
In order to define which PLM palmitoylation site mediates inhibition of the Na pump, we 
generated cell lines expressing C40A or C42A PLM-YFP under the control of a tetracycline-
sensitive promoter. These are characterized by comparing them with cells expressing wild type 
PLM-YFP (1) in Fig S2. Identical quantities of Na pump α1 subunit co-immunoprecipitated with 
PLM-YFP from all three cell lines (Fig S2A). Induction of PLM-YFP expression was without 
effect on the cell surface expression of Na pump α1 subunit in all three cell lines (Fig S2B). In 
keeping with our previous data using the pharmacological DHHC inhibitor 2-bromopalmitate (1), 
in cells where PLM palmitoylation is reduced (Fig S2B – the lines expressing PLM-C40A and 
PLM-C42A) a slightly smaller fraction of non-palmitoylated PLM was found at the cell surface 
 2
compared to WT, but this does not cause a reduction in the amount of Na pump α subunit 
associated (Fig S2A). 
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Figure legends 
 
Figure S1 
Functional analysis of DHHC5. Disorder prediction for human DHHC5, produced using the 
regional order neural network. A very similar disorder profile was observed for murine DHHC5. 
DHHC5 consists of a largely ordered N terminus, including the transmembrane domains (TM, 
annotated) and cysteine rich domain (including the DHHC motif), and a largely disordered C 
terminus. The positions of the truncations are indicated on the disorder prediction.  
 
Figure S2 
Characterization of tet-inducible cell lines expressing PLM-YFP C40A and PLM-YFP C42A A: 
Co-immunoprecipitation (IP) experiments indicate Na pump catalytic subunit co-purifies with 
wild type (WT), C40A and C42A PLM-YFP following induction of expression using 
tetracycline (tet) in FT-293 cells. SM: starting cell lysate. B: Cell surface biotinylation 
experiments indicate identical cell surface expression of the sodium pump α1 subunit following 
induction of wild type, C40A and C42A PLM-YFP in FT-293 cells. Surf: cell surface proteins. 
 
Figure S3 
 3
Disorder predictions for all human DHHC isoforms. Predictions were generated using PONDR-
FIT (7). Positions of transmembrane domains are plotted in black, and the position of the DHHC 
motif plotted in red. Values > 0.5 are predicted to correspond to protein disorder. 
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